139 related articles for article (PubMed ID: 32522271)
1. Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma.
Haase M; Thiel A; Scholl UI; Ashmawy H; Schott M; Ehlers M
BMC Res Notes; 2020 Jun; 13(1):282. PubMed ID: 32522271
[TBL] [Abstract][Full Text] [Related]
2. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
3. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
4. Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R.
Gaujoux S; Hantel C; Launay P; Bonnet S; Perlemoine K; Lefèvre L; Guillaud-Bataille M; Beuschlein F; Tissier F; Bertherat J; Rizk-Rabin M; Ragazzon B
PLoS One; 2013; 8(2):e55743. PubMed ID: 23409032
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
[TBL] [Abstract][Full Text] [Related]
6. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of CTNNB1 in adrenocortical carcinomas: Identification of novel mutations and correlation to survival.
Maharjan R; Backman S; Åkerström T; Hellman P; Björklund P
Sci Rep; 2018 Jun; 8(1):8610. PubMed ID: 29872083
[TBL] [Abstract][Full Text] [Related]
8. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
9. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
10. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
[TBL] [Abstract][Full Text] [Related]
11. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors.
Leal LF; Mermejo LM; Ramalho LZ; Martinelli CE; Yunes JA; Seidinger AL; Mastellaro MJ; Cardinalli IA; Brandalise SR; Moreira AC; Tone LG; Scrideli CA; Castro M; Antonini SR
J Clin Endocrinol Metab; 2011 Oct; 96(10):3106-14. PubMed ID: 21849527
[TBL] [Abstract][Full Text] [Related]
12. Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.
Salomon A; Keramidas M; Maisin C; Thomas M
Oncotarget; 2015 May; 6(13):11421-33. PubMed ID: 25823656
[TBL] [Abstract][Full Text] [Related]
13. β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma.
Gaujoux S; Grabar S; Fassnacht M; Ragazzon B; Launay P; Libé R; Chokri I; Audebourg A; Royer B; Sbiera S; Vacher-Lavenu MC; Dousset B; Bertagna X; Allolio B; Bertherat J; Tissier F
Clin Cancer Res; 2011 Jan; 17(2):328-36. PubMed ID: 21088256
[TBL] [Abstract][Full Text] [Related]
14. RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.
Liu-Chittenden Y; Jain M; Gaskins K; Wang S; Merino MJ; Kotian S; Kumar Gara S; Davis S; Zhang L; Kebebew E
Oncogene; 2017 Jun; 36(25):3541-3552. PubMed ID: 28114280
[TBL] [Abstract][Full Text] [Related]
15. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
[TBL] [Abstract][Full Text] [Related]
16. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome.
Ronchi CL; Sbiera S; Altieri B; Steinhauer S; Wild V; Bekteshi M; Kroiss M; Fassnacht M; Allolio B
Endocr Relat Cancer; 2015 Aug; 22(4):531-43. PubMed ID: 25979380
[TBL] [Abstract][Full Text] [Related]
17. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors.
Chapman A; Durand J; Ouadi L; Bourdeau I
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1477-81. PubMed ID: 21733995
[TBL] [Abstract][Full Text] [Related]
18. Cushing's syndrome in an infant secondary to malignant adrenocortical tumors with somatic mutation of beta-catenin.
Pusantisampan T; Sangkhathat S; Kayasut K; Kanngurn S; Jaruratanasirikul S; Chotsampancharoen T; Kritsaneepaiboon S
Pediatr Dev Pathol; 2010; 13(3):238-42. PubMed ID: 19863445
[TBL] [Abstract][Full Text] [Related]
19. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
[TBL] [Abstract][Full Text] [Related]
20. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.
Sbiera I; Kircher S; Altieri B; Lenz K; Hantel C; Fassnacht M; Sbiera S; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():795116. PubMed ID: 34956100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
